# Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection

> **NIH NIH K01** · UNIVERSITY OF GEORGIA · 2020 · $348,251

## Abstract

Despite tremendous efforts to develop a HIV vaccine, there is currently no vaccine for the prevention of HIV
infection. With the advent of highly successful antiretroviral therapy, mortality and morbidity associated with HIV
infection has been significantly reduced. Unfortunately, opportunistic infections are commonly observed among
HIV-infected patients, and remain a problematic issue that must be urgently addressed. A frequently encountered
HIV-associated opportunistic infection is Pneumocystis pneumonia (PCP), which is caused by the ubiquitous
fungus Pneumocystis jirovecii. Although antiretroviral therapy has reduced the incidence of PCP, 30% of HIV-
infected individuals will develop PCP, which can have unacceptable lethal outcomes despite current drug
treatments. PCP is often a defining disease in infected patients who are unaware of their HIV infection. The goal
of this K01 award is to support the transition of my research program to develop new therapeutics for
opportunistic infections affecting HIV/AIDS patients, and to test these therapeutics in a nonhuman primate (NHP)
model of HIV infection. My previous research has primarily focused on structural mechanisms of bacterial
pathogenesis and antibody-mediated immunity to viral pathogens. Although I have been very successful in my
previous training, I desire additional protected time to transition my research in an exciting and independent
direction to study antibody-mediated immunity to opportunistic pathogens affecting HIV/AIDS patients,
particularly incorporating NHPs, which represent the best model of HIV infection. To complete my training, I am
leveraging the excellent resources at the University of Georgia NHP core, which my primary mentor Dr. Karen
Norris recently established during her move to UGA. The proposed work in this application will focus on the
development of therapeutic antibodies to treat PCP in a NHP model of HIV-infection. My overall hypothesis is
that antibodies specific to the Pneumocystis kexin protease can effectively treat PCP. Dr. Norris has developed
an excellent NHP model of HIV/PCP co-infection, and has identified a protein-based vaccine candidate (KEX1)
based on the Pneumocystis kexin protease. The proposed work will combine my current expertise in antibody
generation with new training in the HIV field under the guidance of Dr. Norris and my clinical mentor Dr. Alison
Morris. In Specific Aim 1 I will determine if antibodies generated in response to KEX1 vaccination can effectively
treat PCP. The KEX1 fragment of the Pneumocystis kexin protein was previously shown to protect against
development of PCP. I will purify KEX1-specific antibodies and test the antibodies for treatment of PCP in a NHP
model of HIV/PCP co-infection. In Specific Aim 2, I will leverage my expertise in human antibody generation to
isolate novel human antibodies specific to the KEX1 protein. The antibodies will be characterized to identify the
top candidate, and the top candidate will be tes...

## Key facts

- **NIH application ID:** 10001636
- **Project number:** 5K01OD026569-03
- **Recipient organization:** UNIVERSITY OF GEORGIA
- **Principal Investigator:** Jarrod Mousa
- **Activity code:** K01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $348,251
- **Award type:** 5
- **Project period:** 2018-09-10 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001636

## Citation

> US National Institutes of Health, RePORTER application 10001636, Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection (5K01OD026569-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10001636. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*